First United States Patient Receives Neovasc's Reducer in Compassionate Use Procedure


June 25, 2018—Neovasc Inc. announced that the first United States patient has been implanted with the Neovasc Reducer for the treatment of refractory angina. The compassionate use case was conducted by Gerald Koenig, MD, along with Ryan Gindi, MD, and colleagues, of the Division of Cardiology at Henry Ford Hospital in Detroit, Michigan. The Reducer has received European CE Mark approval for the treatment of refractory angina.

In Neovasc's announcement, Dr. Koenig commented, "This patient has severe coronary artery disease and has suffered from refractory angina for a few years. The condition has had a significant impact on his quality of life during this time, with little to no relief from multiple other widely accepted treatment options."

Dr. Koenig continued, "This novel device has accumulating evidence supporting the physiologic basis and associated clinical benefit. My experience with the Reducer during the procedure was very positive. The process is similar to implanting a stent. In terms of the patient, he tolerated the procedure very well and had no complications."


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.